Literature DB >> 31403240

Relevance of donor-specific antibody monitoring after kidney transplantation: Findings from the Collaborative Transplant Study and the Heidelberg Transplant Center.

Caner Süsal1, Güclü Aykut1, Christian Morath2, Alexander Fichtner3, Christian Unterrainer1, Sabine Scherer1, Thuong H Tran1, Arianeb Mehrabi4, Martin Zeier2, Burkhard Tönshoff3.   

Abstract

Monitoring of donor-specific HLA antibodies (DSA) has become part of the clinical routine in kidney transplantation. This paper gives a brief overview on data from the Collaborative Transplant Study (CTS) and the Heidelberg Transplant Center on the clinical relevance of post-transplant DSA monitoring in patients undergoing renal transplantation. The obtained findings underline the importance of DSA monitoring in the post-operative course in immunologically high-risk patients and patients with deterioration of graft function. Especially in patients with a pre-activated immune system, a gap in the immunosuppressive therapy appear to lead to persistence, reappearance or de novo occurrence of strong, complement-activating DSA, resulting in severe antibody-mediated rejection (AMR) and, without timely intervention, in AMR-related graft loss.
© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  C1q; antibody-mediated rejection; donor-specific antibodies; graft rejection; graft survival; kidney transplantation; sCD30; tacrolimus; under-immunosuppression

Mesh:

Substances:

Year:  2019        PMID: 31403240     DOI: 10.1111/tan.13665

Source DB:  PubMed          Journal:  HLA        ISSN: 2059-2302            Impact factor:   4.513


  7 in total

Review 1.  Egyptian clinical practice guideline for kidney transplantation.

Authors:  Ahmed A Shokeir; Saddam Hassan; Tamer Shehab; Wesam Ismail; Ismail R Saad; Abdelbasset A Badawy; Wael Sameh; Hisham M Hammouda; Ahmed G Elbaz; Ayman A Ali; Rashad Barsoum
Journal:  Arab J Urol       Date:  2021-01-03

2.  Human leukocyte antigen selected allogeneic mesenchymal stromal cell therapy in renal transplantation: The Neptune study, a phase I single-center study.

Authors:  Geertje J Dreyer; Koen E Groeneweg; Sebastiaan Heidt; Dave L Roelen; Melissa van Pel; Helene Roelofs; Volkert A L Huurman; Ingeborg M Bajema; Dirk Jan A R Moes; Willem E Fibbe; Frans H J Claas; Cees van Kooten; Rabelink J Rabelink; Johan W de Fijter; Marlies E J Reinders
Journal:  Am J Transplant       Date:  2020-05-06       Impact factor: 8.086

3.  Tailored immunosuppression after kidney transplantation - a single center real-life experience.

Authors:  Miriam Good-Weber; Malgorzata Roos; Thomas F Mueller; Barbara Rüsi; Thomas Fehr
Journal:  BMC Nephrol       Date:  2020-11-23       Impact factor: 2.388

4.  Living Donor Kidney Transplantation in Patients With Donor-Specific HLA Antibodies After Desensitization With Immunoadsorption.

Authors:  Florian Kälble; Caner Süsal; Luiza Pego da Silva; Claudius Speer; Louise Benning; Christian Nusshag; Lien Pham; Hien Tran; Matthias Schaier; Claudia Sommerer; Jörg Beimler; Arianeb Mehrabi; Martin Zeier; Christian Morath
Journal:  Front Med (Lausanne)       Date:  2021-12-17

5.  The Clinical Impact of Anti-HLA Donor Specific Antibody Detection Through First Year Screening on Stable Kidney Transplant Recipients.

Authors:  Akhil Sharma; Dana R Jorgensen; Rajil B Mehta; Puneet Sood; Chethan M Puttarajappa; Christine M Wu; Amit D Tevar; Michele Molinari; Adriana Zeevi; Sundaram Hariharan
Journal:  Transpl Int       Date:  2022-03-17       Impact factor: 3.782

Review 6.  Transplanting the Elderly: Mandatory Age- and Minimal Histocompatibility Matching.

Authors:  Geertje J Dreyer; Johan W de Fijter
Journal:  Front Immunol       Date:  2020-03-12       Impact factor: 7.561

7.  Development of De Novo Donor-specific HLA Antibodies and AMR in Renal Transplant Patients Depends on CYP3A5 Genotype.

Authors:  Justa Friebus-Kardash; Ejona Nela; Birte Möhlendick; Andreas Kribben; Winfried Siffert; Falko Markus Heinemann; Ute Eisenberger
Journal:  Transplantation       Date:  2021-07-01       Impact factor: 5.385

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.